Poly (ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint inhibitors, including monoclonal antibodies targeting PD-1 and CTLA-4, have transformed cancer therapy [15]. The gene discussed is CTLA4; the disease is cancer.